Trials: H7N9 Influenza

Phase 2 N=372 Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMT) of Serum Hemagglutinin Inhibition (HAI) Antibodies — 23.3; 19.9; 24.2; 6.0 titer

National Institute of Allergy and Infectious… Results May 2021 3.2% serious AE View details

Phase 2 N=180 2013/2017 H7N9 Prime-Boost Interval

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutinin Inhibition (HAI) Antibodies Against the Influenza A/H7N9 Study Vaccine Viruses on Day 43 in Participants Who Received…

National Institute of Allergy and Infectious… Results Aug 2021 2.2% serious AE View details

Phase 2 N=304 2017 A/H7N9 IIV Revaccination

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMT) of Serum Hemagglutination Inhibition (HAI) Antibodies on Day 22 Against the 2017 Influenza A/H7N9 Vaccine Virus — 22.7; 116.1; 77.7; 190.3…

National Institute of Allergy and Infectious… Results Jul 2021 0.7% serious AE View details

Phase 2 N=30 H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Avian Influenza · H1N1 Influenza · Influenza

Primary: Percentage of Participants Achieving Seroconversion Based on HAI Titer (A/H7N9 Vaccine, With and Without Adjuvant) — 80.0; 0 percentage of participants

National Institute of Allergy and Infectious… Results Jan 2022 3.3% serious AE View details

Phase 1 N=402 Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

H7N9 Influenza

Primary: Geometric Mean Titers Of Subjects After Each Vaccination Of a Cell-Culture Derived H7N9c Monovalent Vaccine, Hemagglutination Inhibition Assay (Day 43) — 5; 5; 5; 5.05…

Novartis Vaccines Results May 2015 2.0% serious AE View details

Phase 2 N=720 Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Avian Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies — 33.6; 33.5; 39.2; 5.5 titer

National Institute of Allergy and Infectious… Results Oct 2020 2.9% serious AE View details

Phase 2 N=149 Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Avian Influenza · Influenza · Influenza Immunisation

Primary: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Antibodies Against the 2017 H7N9 Inactivated Influenza Vaccine (IIV) Strain After Second H7N9…

National Institute of Allergy and Infectious… Results Aug 2020 0.7% serious AE View details

Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Influenza · Influenza Vaccines

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

GlaxoSmithKline Results Feb 2020 0.8% serious AE View details

Phase 2 N=275 Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Influenza

Primary: Number of Subjects With a Hemagglutination Inhibition (HI) Antibody Response to the Vaccine Strain (A/H9N2/Chicken/Hong Kong/G9/97) Associated With Seroconversion 21…

Alachua Government Services, Inc. Results Feb 2023 0.0% serious AE View details

Phase 2 N=833 A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Influenza, Human

Primary: Percentage of Seroprotected Participants for Anti-hemagglutination Inhibition (HI) Antibodies Against Vaccine-homologous H7N9 — 27.1; 27.7; 23.5; 26.5 Percentage of…

GlaxoSmithKline Results Oct 2023 4.6% serious AE View details

Phase 2 N=505 H5N1 Priming and Boosting Strategies

Influenza

Primary: Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen — 14.7; 27.9; 6.7; 13.6 Titer

National Institute of Allergy and Infectious… Results Jul 2010 0.4% serious AE View details

Phase 1 N=40 Safety Trial of Live Attenuated Influenza (H7N3) Vaccine

Influenza · Avian Influenza

Primary: Number of Participants With Immediate Reactions — 0; 0; 0; 0 Participants

PATH Results Apr 2019 0.0% serious AE View details

Phase 2 N=326 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza

Influenza · Avian Influenza · Severe Influenza

Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42

National Institute of Allergy and Infectious… Results May 2014 0.3% serious AE View details

Phase 3 N=5,071 Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants

GlaxoSmithKline Results Aug 2017 1.1% serious AE View details

Phase 2 N=260 A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Influenza, Human · Influenza in Birds · Respiratory Tract Infections

Primary: Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HI) Antibodies Against the H5N6 Strain — 5.48; 5.55; 5.47; 20.39 titer

Seqirus Results May 2026 3.9% serious AE View details

Phase 3 N=3,196 A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

Avian Influenza

Primary: Primary Immunogenicity Endpoint: Geometric Mean Titer (GMT) at Day 43 by Lot — 16.1; 17.0; 17.0; 128.6 geometric mean titer

Seqirus Results Apr 2019 7.4% serious AE View details

N/A N=46 Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Influenza

Primary: Area Under the Curve of Virus Load — -2081.98; 18,973.90; 15,944.09; 12,201.14 mins*Eq log10 TCID50/mL

Hvivo Results Jan 2020 0.0% serious AE View details

Phase 4 N=12 Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Influenza A Subtype H5N1 Infection

Primary: Number of Participants With a Four-fold Increase in Stem-specific Antibody Titers (H5, Hemagglutinin Antibody) Against H5N1 at Day 29 After Vaccination With the Seasonal…

Emory University Results Mar 2020 0.0% serious AE View details

Phase 1 N=40 Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

Influenza

Primary: Adverse Events by Severity — 20; 8; 25; 8 Participants

PATH Results Nov 2018 0.0% serious AE View details

Phase 1 N=75 Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

Influenza A Subtype H5N1 Infection

Primary: Immediate Reactions Occurring Within 60 Minutes of Administration of Any Dose — 0; 0; 0; 0 Participants

Institute of Vaccines and Medical Biologicals… Results Mar 2019 0.0% serious AE View details

Phase 2 N=405 Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects

Pandemic · Avian Influenza

Primary: Number Subjects Who Responded to Two or Three Vaccinations of the MF59-H5N1 Influenza Vaccine — 0; 1; 0; 2 Subjects

Novartis Results Feb 2013 3.5% serious AE View details

Phase 1 N=32 Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Influenza

Primary: Fold Rise in Titer of Anti-group 1 Stalk-antibodies in Recipients of the Pandemic Live Attenuated Influenza Vaccines (pLAIVs) (H2N2, H6N1 and H9N2) Compared to the…

National Institute of Allergy and Infectious… Results Sep 2025 3.2% serious AE View details

Phase 2 N=43 Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Primary: Geometric Mean Titer of Serum Hemagglutination Inhibition Antibody Response to A/17/Duck/Potsdam/86/92 (H5N2) LAIV Strain Following Administration of A(H5N1) Inactivated…

PATH Results Feb 2019 0.0% serious AE View details

Phase 2 N=1,393 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

Primary: The Percentages Of Subjects Achieving Hemagglutination Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 12; 10; 81; 63 Percentages of subjects

Novartis Vaccines Results Aug 2015 6.8% serious AE View details

Phase 2 N=50 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

Primary: Change in Traditional Immune Parameters Measurements Using Luminex Assays and Gene Expression Measurement Using Microarray Experiments From Baseline With Influenza A…

National Institute of Allergy and Infectious… Results Feb 2019 2.0% serious AE View details

Phase 2 N=48 Influenza A 2009 H1N1 Challenge Study in Healthy Adults

Influenza

Primary: Percent MMID — 0; 0; 20; 47 percentage of participants

National Institute of Allergy and Infectious… Results May 2016 0.0% serious AE View details

Phase 2 N=720 Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Influenza A Virus, H5N1 Subtype

Primary: Number of Local Adverse Reactions to 2-dose and 3-dose H5 Influenza Vaccination Series — 43; 32; 35; 37 Events

Biomedical Advanced Research and Development… Results Jul 2020 1.9% serious AE View details

Phase 2 N=979 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Pandemic H5N1 Influenza

Primary: Percentages Of Subjects Achieving Hemagglutinin Inhibition (HI) Titers ≥40 Against A/H5N1 Strain. — 4; 4; 85; 63 Percentages of subjects

Novartis Vaccines Results Feb 2015 2.9% serious AE View details

Phase 3 N=844 Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules

Influenza

Primary: Number of Subjects Boosted at Month 12 With Haemagglutinin-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 178 Participants

GlaxoSmithKline Results Aug 2018 6.5% serious AE View details

Phase 1 N=60 Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults

Influenza · Healthy

Primary: Solicted Adverse Events — 8; 12; 13; 14 participants

Rebecca Cox Results Dec 2016 0.0% serious AE View details

Clinical Trial Search

Phase 2 N=372 Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Phase 2 N=180 2013/2017 H7N9 Prime-Boost Interval

Phase 2 N=304 2017 A/H7N9 IIV Revaccination

Phase 2 N=30 H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses

Phase 1 N=402 Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years

Phase 2 N=720 Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Phase 2 N=149 Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Phase 2 N=385 Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population

Phase 2 N=275 Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Phase 2 N=833 A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Phase 2 N=505 H5N1 Priming and Boosting Strategies

Phase 1 N=40 Safety Trial of Live Attenuated Influenza (H7N3) Vaccine

Phase 2 N=326 High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza

Phase 3 N=5,071 Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above

Phase 2 N=260 A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Phase 3 N=3,196 A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

N/A N=46 Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model

Phase 4 N=12 Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

Phase 1 N=40 Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine

Phase 1 N=75 Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

Phase 2 N=405 Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects

Phase 1 N=32 Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Phase 2 N=43 Immunogenicity of H5N1 Vaccine Following H5N2

Phase 2 N=1,393 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Phase 2 N=50 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Phase 2 N=48 Influenza A 2009 H1N1 Challenge Study in Healthy Adults

Phase 2 N=720 Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Phase 2 N=979 Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Phase 3 N=844 Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules

Phase 1 N=60 Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults